Hemab Therapeutics (COAG) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.44 billion vs $1.01 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | MGTX |
|---|---|---|
| Share price | $30.89 | $10.50 |
| Market cap | $1.44B | $1.01B |
| 1-day change | +7.63% | -2.96% |
| YTD return | — | +32.08% |
| 1-year return | — | +27.12% |
| 5-year return | — | -26.47% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-4.64 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $15.35 |
| 52-week low | $23.00 | $6.62 |
| Distance from 52-week high | -44.26% | -31.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.12% | +164.29% |
| Average volume | 458.71K | 792.38K |
| Shares outstanding | 46.71M | 96.04M |
| Employees | 59 | 393 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Hemab Therapeutics in Health Care and MeiraGTx in Healthcare.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Healthcare · Biotechnology · 393 employees
COAG vs MGTX FAQ
Which is bigger, Hemab Therapeutics or MeiraGTx?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.44B compared with $1.01B for MeiraGTx (MGTX).
Are Hemab Therapeutics and MeiraGTx in the same industry?
No. Hemab Therapeutics is in the Health Care sector, while MeiraGTx is in Healthcare.